Suppr超能文献

比较常规干血斑和体积吸收微采样法测定他克莫司和霉酚酸。

Comparison of conventional dried blood spots and volumetric absorptive microsampling for tacrolimus and mycophenolic acid determination.

机构信息

Toxicology Service, Institute of Forensic Sciences, Universidade de Santiago de Compostela, Rúa San Francisco, s/n, 15782 Santiago de Compostela, Spain.

Abdominal Trasplant Unit, Universitary Clinical Hospital of Santiago de Compostela, Rúa da Choupana, s/n, 15706 Santiago de Compostela, Spain.

出版信息

J Pharm Biomed Anal. 2022 Jan 20;208:114443. doi: 10.1016/j.jpba.2021.114443. Epub 2021 Oct 26.

Abstract

Therapeutic drug monitoring (TDM) of immunosuppressants is essential to avoid either rejection or toxicity after solid organ transplantations. Capillary microsampling approaches are an outstanding alternative to conventional venous sampling for TDM (easy and non-invasive collection, enabling self-sampling, and cost-saving shipment, processing and storage). Volumetric absorptive microsampling (VAMS) has gained importance in the last years, as it was meant to overcome the hematocrit (Hct) related issues commonly associated to DBS analysis. Despite all the benefits, microsampling techniques performance (including a thorough clinical validation) should be set up before their implementation in clinical practice. The aim of this study was to perform a clinical validation for both tacrolimus (TAC) and mycophenolic acid (MPA) in both DBS and Mitra™ VAMS. For the clinical validations, two different requirements were set up: analytical (following EMA and FDA guidelines) and clinical (following the Royal College of Pathologists of Australasia -RCPA- recommendations) acceptance criteria. For DBS, both analytical and clinical acceptance criteria were fulfilled for TAC, with 98.7% and 95% of the paired samples within the preset limits, respectively. For MPA, the analytical criterion was met (70.6% of paired specimens), although only half of the pairs were within the clinical limits. For VAMS, the clinical validation for both TAC and MPA showed good correlations but significant lower concentrations in VAMS compared to the routine matrices. After VAMS concentrations correction, the analytical requirement was fulfilled for both analytes (71.1% for TAC, 75% for MPA), although the more restrictive criteria recommended by the RCPA were not met for any analyte (half of the samples fell within the acceptance area). In addition, no significant Hct impact on the quantification was found in any case. Also, a preliminary home-sampling trial was set up, showing promising results. Moreover, a comparison between VAMS vs. DBS analytical and clinical performances was carried out, including a home-sampling trial, sample quality results and costs. Although the analytical performance for both VAMS and DBS was similar, DBS were superior regarding clinical criteria, sampling quality and cost.

摘要

在实体器官移植后,为避免排斥反应或毒性,免疫抑制剂的治疗药物监测(TDM)至关重要。毛细血管微采样方法是 TDM 的一种出色替代方法,与传统静脉采样相比,它具有易于操作、非侵入性采集、便于自我采样、节省运输、处理和存储成本的优势。近年来,体积吸收微采样(VAMS)变得越来越重要,因为它旨在克服与 DBS 分析相关的血细胞比容(Hct)问题。尽管微采样技术具有诸多优势,但在将其应用于临床实践之前,应先建立其性能(包括全面的临床验证)。本研究的目的是对 DBS 和 Mitra™ VAMS 中的他克莫司(TAC)和霉酚酸(MPA)进行临床验证。对于临床验证,设定了两个不同的要求:分析(遵循 EMA 和 FDA 指南)和临床(遵循皇家病理学家学院 -RCPA- 建议)接受标准。对于 DBS,TAC 的分析和临床接受标准均得到满足,分别有 98.7%和 95%的配对样本在预设范围内。对于 MPA,分析标准得到满足(70.6%的配对样本),尽管只有一半的配对样本在临床范围内。对于 VAMS,TAC 和 MPA 的临床验证相关性良好,但与常规基质相比,VAMS 的浓度显著降低。对 VAMS 浓度进行校正后,两种分析物均满足分析要求(TAC 为 71.1%,MPA 为 75%),但没有任何一种分析物符合 RCPA 推荐的更严格标准(一半的样本落在接受区域内)。此外,在任何情况下,都没有发现 Hct 对定量有显著影响。此外,还进行了初步的家庭采样试验,结果很有前景。此外,还对 VAMS 与 DBS 的分析和临床性能进行了比较,包括家庭采样试验、样本质量结果和成本。尽管 VAMS 和 DBS 的分析性能相似,但 DBS 在临床标准、采样质量和成本方面具有优势。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验